Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Mugneret

Showing results (11-20 of 66) with videos related to

Pageof 7
Sort By:
Comptes Rendus Des Seances De La Societe De Biologie Et De Ses Filiales|January 1, 1988
[Immunocytologic study of light cell lines established in vitro from Ewing's sarcoma. Identification of neural markers]S Lizard-Nacol, E Justrabo, F Mugneret, et al.
International Journal of Cancer|July 29, 1996
An EWS/ERG fusion with a truncated N-terminal domain of EWS in a Ewing's tumorM Peter, F Mugneret, A Aurias, et al.
Nouvelle Revue Francaise D'Hematologie|January 1, 1989
Myeloproliferative disorders in the department of Côte d'Or between 1980 and 1986D Heudes, P M Carli, F Bailly, et al.
Cancer Genetics and Cytogenetics|September 1, 1988
Association of breakpoint 14q23 with uterine leiomyomaF Mugneret, S Lizard-Nacol, C Volk, et al.
Journal De Genetique Humaine|January 1, 1988
[Translocation (X; Y) and genetic counseling]F Mugneret, I Sidaner, A Nivelon-Chevallier, et al.
Leukemia|February 1, 1995
Der(16)t(1;16)(q10;p10) in multiple myeloma: a new non-random abnormality that is frequently associated with Burkitt's-type translocationsF Mugneret, I Sidaner, B Favre, et al.
British Journal of Haematology|May 1, 1995
Der(16)t(1;16)(q11;q11) in myelodysplastic syndromes: a new non-random abnormality characterized by cytogenic and fluorescence in situ hybridization studiesF Mugneret, N Dastugue, B Favre, et al.
British Journal of Cancer|July 1, 1996
Epidemiological characteristics of myelodysplastic syndrome in a well-defined French populationM Maynadié, C Verret, P Moskovtchenko, et al.
Leukemia|June 24, 2000
Increase therapy-related leukemia secondary to breast cancerP M Carli, C Sgro, N Parchin-Geneste, et al.
The Journal of Experimental Medicine|October 1, 1992
A third tal-1 promoter is specifically used in human T cell leukemiasO Bernard, O Azogui, N Lecointe, et al.
Pageof 7

Showing results (11-20 of 66) with videos related to

Sort By:
Pageof 7
Comptes Rendus Des Seances De La Societe De Biologie Et De Ses Filiales|January 1, 1988
[Immunocytologic study of light cell lines established in vitro from Ewing's sarcoma. Identification of neural markers]S Lizard-Nacol, E Justrabo, F Mugneret, et al.
International Journal of Cancer|July 29, 1996
An EWS/ERG fusion with a truncated N-terminal domain of EWS in a Ewing's tumorM Peter, F Mugneret, A Aurias, et al.
Nouvelle Revue Francaise D'Hematologie|January 1, 1989
Myeloproliferative disorders in the department of Côte d'Or between 1980 and 1986D Heudes, P M Carli, F Bailly, et al.
Cancer Genetics and Cytogenetics|September 1, 1988
Association of breakpoint 14q23 with uterine leiomyomaF Mugneret, S Lizard-Nacol, C Volk, et al.
Journal De Genetique Humaine|January 1, 1988
[Translocation (X; Y) and genetic counseling]F Mugneret, I Sidaner, A Nivelon-Chevallier, et al.
Leukemia|February 1, 1995
Der(16)t(1;16)(q10;p10) in multiple myeloma: a new non-random abnormality that is frequently associated with Burkitt's-type translocationsF Mugneret, I Sidaner, B Favre, et al.
British Journal of Haematology|May 1, 1995
Der(16)t(1;16)(q11;q11) in myelodysplastic syndromes: a new non-random abnormality characterized by cytogenic and fluorescence in situ hybridization studiesF Mugneret, N Dastugue, B Favre, et al.
British Journal of Cancer|July 1, 1996
Epidemiological characteristics of myelodysplastic syndrome in a well-defined French populationM Maynadié, C Verret, P Moskovtchenko, et al.
Leukemia|June 24, 2000
Increase therapy-related leukemia secondary to breast cancerP M Carli, C Sgro, N Parchin-Geneste, et al.
The Journal of Experimental Medicine|October 1, 1992
A third tal-1 promoter is specifically used in human T cell leukemiasO Bernard, O Azogui, N Lecointe, et al.
Pageof 7